Discovery Laboratories is a biotechnology company developing its proprietary surfactant technology as surfactant replacement therapies for respiratory diseases. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs ability to absorb oxygen and to maintain proper airflow through the respiratory system. The absence or depletion of surfactants is involved in a number of respiratory diseases. The company s technology produces a precision-engineered surfactant that is designed to mimic the essential properties of natural human lung surfactant. Discovery Laboratories SRT pipeline is focused on the most significant respiratory conditions prevalent in the neonatal intensive care unit. Surfaxin is one of the company s leading products for the prevention of respiratory distress syndrome in premature infants. SRT technology is also being developed to address the various respiratory conditions affecting pediatric, young adult and adult patients in the critical care and other hospital settings. Discovery Laboratories is located in Warrington, Pa.